Latigo reports Q3 2026 results, names new CEO, adds opioid arm to Phase 3 trialNov 5Quarterly updateCollegium Pharmaceutical, IncLatigo Biotherapeutics
Pfizer raises 2026 guidance after Q3, reports pipeline progress and new CFONov 3Quarterly updateBioNTech SEC4 Therapeutics, Inc.
IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Merck posts Q3 2026 results with oncology approvals and new sac-TMT regulatory filingOct 29Quarterly updateGilead SciencesMerck & Co., Inc.
Artiva Biotherapeutics halts AlloNK development, cuts staff by 94%Oct 27Quarterly updateArtiva Biotherapeutics, Inc.Biogen
Sign inSign in